[Treatment of motor symptoms in Parkinson's disease].
BACKGROUND
The physiopathology of the motor symptoms is the best known aspect of the Parkinson's disease. This knowledge led us to use several drugs and therapeutic strategies to improve these features of the Parkinson's disease.


CONCLUSIONS
Mainly based in the theory of continuous dopaminergic stimulation, new drugs, new routes of administration and new galenic formulations have been developed, as well surgical procedures and other therapies have been introduced to improve the management of patients with long diseases without a responses to the classic therapies. At the same time, several often-used drugs have disappeared due to its non-parkinsonian adverse effects and also the influence in quality of life of non-motor parkinsonian adverse effects have been ultimately recognized.
Morís-De la Tassa
G
G
Sección de Neurología, Hospital San Agustín, Camino de Heros, 4. E-33400 Avilés, Asturias, España, gmorist@gmail.com
Arias-Rodríguez
M
M
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D065098:Catechol O-Methyltransferase Inhibitors; D015259:Dopamine Agents / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology
D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D015259:Dopamine Agents; D008996:Monoamine Oxidase Inhibitors; D007980:Levodopa